Search Medical Condition
Please enter condition
Please choose location

Schertz, Texas Clinical Trials

A listing of Schertz, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (75) clinical trials

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

The study is a prospective, dose-finding, randomized, parallel group, double-blind, placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the treatment of 330 women with moderate-to-severe endometriosis associated pain. Subject will be randomized to one of 6 treatment groups in a 1:1:1:1:1:1 ratio (1 placebo group, 5 ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

The duration of the study period is up to 87 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks and a 2 week single blind Run-in phase, a 26 week double-blind Core Treatment Period, a 53-week double-blind Extension Period, a 4 week post treatment ...

Phase

0.0 miles

Learn More »

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Phase

0.0 miles

Learn More »

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...

Phase

1.92 miles

Learn More »

A Study of SIMPONI to Arrest Beta-cell Loss in Type 1 Diabetes

The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).

Phase

1.92 miles

Learn More »

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Up to 34 weeks, including a Screening Period consisting of a Screening Phase of up to 2 weeks and a 2-week single-blind placebo Run-in Phase, a 26-week double-blind Treatment Period, and a 4-week post-treatment Follow-up visit to collect safety information.

Phase

1.92 miles

Learn More »

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

Phase

1.92 miles

Learn More »

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

This is a Phase II randomized, double-blind, placebo-controlled study for dose selection in postmenopausal women with moderate to severe VMS, defined as follows: - Moderate: sensation of heat with sweating, able to continue activity - Severe: sensation of heat with sweating, causing cessation of activity This study is comprised of ...

Phase

1.92 miles

Learn More »

Safety Tolerability and Efficacy of Selonsertib GS-0976 and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)

The primary objective of this study is to evaluate the safety and tolerability of selonsertib (SEL; formerly GS-4997), GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis (NASH).

Phase

4.11 miles

Learn More »

Safety Tolerability and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in adults with primary sclerosing cholangitis (PSC).

Phase

4.11 miles

Learn More »